首页> 美国卫生研究院文献>World Journal of Gastrointestinal Oncology >Differential colorectal carcinogenesis: Molecular basis and clinical relevance
【2h】

Differential colorectal carcinogenesis: Molecular basis and clinical relevance

机译:差异性结直肠癌的发生:分子基础和临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colorectal cancer (CCR) is one of the most frequent cancers in developed countries. It poses a major public health problem and there is renewed interest in understanding the basic principles of the molecular biology of colorectal cancer. It has been established that sporadic CCRs can arise from at least two different carcinogenic pathways. The traditional pathway, also called the suppressor or chromosomal instability pathway, follows the Fearon and Vogelstein model and shows mutation in classical oncogenes and tumour suppressor genes, such as K-ras, adenomatous polyposis coli, deleted in colorectal cancer, or p53. Alterations in the Wnt pathway are also very common in this type of tumour. The second main colorectal carcinogenesis pathway is the mutator pathway. This pathway is present in nearly 15% of all cases of sporadic colorectal cancer. It is characterized by the presence of mutations in the microsatellite sequences caused by a defect in the DNA mismatch repair genes, mostly in hMLH1 or hMSH2. These two pathways have clear molecular differences, which will be reviewed in this article, but they also present distinct histopathological features. More strikingly, their clinical behaviours are completely different, having the “mutator” tumours a better outcome than the “suppressor” tumours.
机译:大肠癌(CCR)是发达国家中最常见的癌症之一。它带来了一个主要的公共卫生问题,人们对理解结直肠癌分子生物学的基本原理有了新的兴趣。已经确定,零星的CCR可以来自至少两种不同的致癌途径。传统途径也称为抑制子或染色体不稳定途径,遵循Fearon和Vogelstein模型并显示出经典致癌基因和抑癌基因(如K-ras,腺瘤性息肉病大肠埃希菌,在大肠癌或p53中缺失)的突变。 Wnt途径的改变在这种类型的肿瘤中也很常见。第二个主要的大肠癌发生途径是突变体途径。在所有散发性结直肠癌病例中,近15%存在这种途径。其特征是微卫星序列中存在突变,这种突变是由DNA错配修复基因的缺陷引起的,主要是在hMLH1或hMSH2中。这两种途径具有明显的分子差异,本文将对此进行综述,但它们也呈现出独特的组织病理学特征。更惊人的是,它们的临床行为完全不同,“突变型”肿瘤比“抑制型”肿瘤的结局更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号